Acute Coronary Syndromes

Acute coronary syndrome (ACS) is most commonly caused by a heart attack (myocardial infarction) where blood flow to the heart is suddenly blocked. This is usually caused by a blood clot from a ruptured coronary artery atherosclerotic plaque. Other causes include spontaneous coronary artery dissection (SCAD), which most commonly occurs in women. ACS is usually treated in a cath lab with angioplasty and the placement of a stent to prop the vessel open.

New drug reverses antiplatelet effects of ticagrelor, helping surgeons avoid a 'bloody mess'
Deepak Bhatt, MD, believes bentracimab could be a game-changer if it gains approval. "I think it's the sort of drug that every emergency room and ICU would have to stock," he said. "A cardiac care unit would have to stock a couple of doses, as would every cath lab."
Late-breaking cardiovascular drug trials took center stage at ACC.25
Richard Kovacs, MD, detailed some the most important late-breaking cardiology pharmacology trials presented at ACC.25.
Plant-based diets may help patients with diabetes, heart disease live longer
Researchers focused on data from nearly 78,000 adults with cardiometabolic disorders, sharing their findings at ACC.25 in Chicago.
Oral semaglutide reduces heart risks while helping patients move past ‘fear of the needle’
Researchers still think patients should receive an injectable version of semaglutide when possible, but new data out of ACC.25 confirm that an oral formulation of the drug is associated with significant benefits.
FDA sees promise in new AI model for heart attack detection
Powerful Medical's advanced algorithm was designed to detect STEMI and STEMI-equivalent patterns in a patient’s ECG results.

HeartFlow sharing new data on AI-enabled CAD management at TCT 2024

The California-based company, fresh off receiving expanded Medicare coverage and a new Category I CPT code for its AI offerings, will have a significant presence at TCT 2024.

New Category I CPT code issued for AI-enabled coronary plaque analysis software

The news comes just days after CMS confirmed these technologies would start receiving expanded Medicare coverage in November. HeartFlow and other AI vendors have already shared their excitement over the decision.

COVID from a patient's nasal passage. Transmission electron micrograph of SARS-CoV-2 virus particles (gold) within endosomes of a heavily infected nasal olfactory epithelial cell. Image captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Image courtesy of NIAID. What does COVID look like?

History of COVID-19 doubles long-term risk of heart attack, stroke or death

A patient's blood type appears to play a major role in their odds of developing cardiovascular issues after COVID-19, researchers found.

CMS updates Medicare coverage for AI-powered coronary plaque assessments

The new policy goes into effect in November, improving Medicare coverage for a technology that has rapidly gained momentum in recent years.

Deaths related to obesity have skyrocketed in the United States, especially among men. However, researchers identified positive progress when it came to the mortality rates for CVD, ischemic heart disease and heart failure/cardiomyopathy.

AstraZeneca spends up to $1.9B for new heart disease drug

Early data suggest the drug, an oral lipoprotein (a) disruptor, could make a significant impact on patient care. AstraZeneca will pay $100 million upfront, with much more to follow if certain milestones are met.

Ultrafast/high frame rate myocardial contrast echocardiography

Ultrafast myocardial contrast echocardiography shows early potential to evaluate CAD

Ultrafast MCE could go on to become a go-to treatment option for obstructive coronary artery disease, according to the authors of a new first-in-human clinical study.

Do cancer treatments increase a patient's risk of cardiovascular disease?

Older cancer survivors appear to face higher risks of stroke, heart attack and heart failure. Early screening and preventative measures can help.

Acute Coronary Syndromes

New drug reverses antiplatelet effects of ticagrelor, helping surgeons avoid a 'bloody mess'

Late-breaking cardiovascular drug trials took center stage at ACC.25

Plant-based diets may help patients with diabetes, heart disease live longer

Oral semaglutide reduces heart risks while helping patients move past ‘fear of the needle’

FDA sees promise in new AI model for heart attack detection